Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma

29 May 2025

Abstract excerpt

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer. While DNA damaging agents such as platinum and PARP inhibitors have derived clinical benefits, acquired resistance invariably develops. Hence there is an urgent need for novel therapeutic strategies to overcome acquired resistance. METHODS: Clinically relevant resistance in PDAC patient-derived cell lines was achieved by extended...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40442403
DOI: 10.1038/s41416-025-03051-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinomaPMID 40442403Read ↗

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.Semantic proximity Read ↗

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.Semantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Targeting BRCA and PALB2 in Pancreatic Cancer.Semantic proximity Read ↗

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsSemantic proximity Read ↗

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent TumorsSemantic proximity Read ↗

Targeting DNA Damage Response and Replication Stress in Pancreatic CancerSemantic proximity Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

Targeting the DNA damage response protein ATR kinase in pancreatic cancerSemantic proximity Read ↗

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA DamageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.